BR112015031416A2 - métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico - Google Patents

métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico

Info

Publication number
BR112015031416A2
BR112015031416A2 BR112015031416A BR112015031416A BR112015031416A2 BR 112015031416 A2 BR112015031416 A2 BR 112015031416A2 BR 112015031416 A BR112015031416 A BR 112015031416A BR 112015031416 A BR112015031416 A BR 112015031416A BR 112015031416 A2 BR112015031416 A2 BR 112015031416A2
Authority
BR
Brazil
Prior art keywords
methods
acid
health
alpha lipoic
administering
Prior art date
Application number
BR112015031416A
Other languages
English (en)
Inventor
Hondmann Dirk
K Poels Eduard
Chenzhong Kuang
Xiao Yan
Jouni Zeina
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of BR112015031416A2 publication Critical patent/BR112015031416A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

a presente descrição refere-se a métodos para a promoção da saúde e/ou do desenvolvimento neuronal em um indivíduo, por meio do fornecimento de composições nutricionais compreendendo ácido docosa-hexaenoico e o ácido alfa-lipoico. a composição nutricional pode incluir ainda lactoferrina, um prebiótico, um probiótico, e misturas dos mesmos. adicionalmente, a presente descrição fornece métodos para acelerar o desenvolvimento da atividade neuronal e/ou o reforço da sinalização por sinapse eletroquímica, fornecendo a(s) composição(ões) nutricional(is), aqui revelada(s), a um indivíduo alvo.
BR112015031416A 2013-07-16 2014-06-21 métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico BR112015031416A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/942,827 US9226914B2 (en) 2013-07-16 2013-07-16 Methods for promoting neuronal development and/or health
PCT/US2014/043532 WO2015009407A1 (en) 2013-07-16 2014-06-21 Methods for promoting neuronal development and/or health comprising administration of a combination of docosahexaenoic acid and alpha-lipoic acid

Publications (1)

Publication Number Publication Date
BR112015031416A2 true BR112015031416A2 (pt) 2017-07-25

Family

ID=51210794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031416A BR112015031416A2 (pt) 2013-07-16 2014-06-21 métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico

Country Status (13)

Country Link
US (1) US9226914B2 (pt)
EP (1) EP3102196A1 (pt)
CN (1) CN105358144B (pt)
AR (1) AR096942A1 (pt)
AU (1) AU2014290767A1 (pt)
BR (1) BR112015031416A2 (pt)
CA (1) CA2918460A1 (pt)
HK (1) HK1221658A1 (pt)
MX (1) MX2016000423A (pt)
PH (1) PH12016500025A1 (pt)
SG (1) SG11201510330YA (pt)
TW (1) TW201542101A (pt)
WO (1) WO2015009407A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150290261A1 (en) * 2014-04-10 2015-10-15 Mead Johnson Nutrition Company Methods of use for probiotics and prebiotics
US10525016B2 (en) * 2015-06-03 2020-01-07 Mead Johnson Nutrition Company Nutritional compositions containing an elevated level of inositol and uses thereof
US10617701B2 (en) * 2015-07-10 2020-04-14 Mead Johnson Nutrition Company Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61701B1 (en) 1986-07-17 1994-11-30 Morinaga Milk Industry Co Ltd Process for producing bovine lactoferrin in high purity
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
DK165090D0 (da) 1990-07-09 1990-07-09 Kem En Tec As Konglomererede partikler
NZ241359A (en) 1991-01-24 1994-08-26 Martek Corp Supplementation of infant formula by the addition of at least two different polyunsaturated fatty acids obtained from at least two different microbial sources; compositions comprising such oils
US5374567A (en) 1993-05-20 1994-12-20 The United States Of America As Represented By The Secretary Of The Navy Operational amplifier using bipolar junction transistors in silicon-on-sapphire
EP1142484A2 (en) 1994-02-16 2001-10-10 Pharming Intellectual Property BV Isolation of lactoferrin from milk
SE9503926D0 (sv) 1995-11-07 1995-11-07 Pharmacia Biotech Ab Adsorptionsförfarande och separationsmedium
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
US6620326B1 (en) 1998-06-18 2003-09-16 Upfront Chromatography A/S Expanded bed adsorption system
AU5823801A (en) 2000-05-12 2001-11-20 Upfront Chromatography As A bed adsorption system
US6332533B1 (en) 2000-08-29 2001-12-25 H.H.H. Incorprorated Media holder mouse pad
ATE455468T1 (de) 2001-06-01 2010-02-15 Upfront Chromatography As Fraktionierung von proteinhaltigen mischungen
DK1480524T3 (da) 2002-03-07 2013-07-15 Upfront Chromatography As Fremgangsmåde til isolering af lactoferrin
US20050107338A1 (en) 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
WO2006009438A2 (en) * 2004-07-19 2006-01-26 N.V. Nutricia Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies
US8883814B2 (en) 2006-06-05 2014-11-11 Keyview Labs, Inc. Compositions and methods for enhancing brain function
US20080003330A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
EP2251030A1 (en) 2009-05-12 2010-11-17 Nestec S.A. Lactoferrin and brain health and development in infants
EP2258218A1 (en) 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
MY173944A (en) 2009-10-29 2020-02-28 Nestec Sa Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof
US9226521B2 (en) * 2009-12-08 2016-01-05 Nestec S.A. Infant formula with probiotics and milk fat globule membrane components
WO2011121151A1 (es) * 2010-03-31 2011-10-06 Vegenat, S.A. Suplemento alimenticio funcional especialmente destinado para la nutrición, prevención y mejora en casos de alteraciones neurológicas, neurodegenerativas o trastornos cognitivos
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
CN102318827B (zh) 2011-07-15 2013-02-27 浙江康恩贝健康产品有限公司 一种促进神经系统发育的营养素组合物及保健品
EP2609814A1 (en) 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of cognitive function
US20140179775A1 (en) 2012-02-29 2014-06-26 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
US20140199265A1 (en) 2013-01-11 2014-07-17 Mead Johnson Nutrition Company Nutritional compositions containing a neurologic component and uses thereof

Also Published As

Publication number Publication date
CA2918460A1 (en) 2015-01-22
CN105358144B (zh) 2018-05-11
EP3102196A1 (en) 2016-12-14
US9226914B2 (en) 2016-01-05
US20150023923A1 (en) 2015-01-22
MX2016000423A (es) 2016-04-20
AU2014290767A1 (en) 2015-12-24
SG11201510330YA (en) 2016-01-28
TW201542101A (zh) 2015-11-16
PH12016500025A1 (en) 2016-03-28
CN105358144A (zh) 2016-02-24
HK1221658A1 (zh) 2017-06-09
WO2015009407A1 (en) 2015-01-22
AR096942A1 (es) 2016-02-10

Similar Documents

Publication Publication Date Title
BR112016024850A2 (pt) composições e métodos para modulação da expressão 3 semelhante a antiopoietina
BR112015015898A2 (pt) composição farmacêutica de solução sólida
BR112015031416A2 (pt) métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico
BR112015005894A2 (pt) composição farmacêutica
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112014016251A2 (pt) composições e métodos para modificação da flora gastrointestinal
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112015015870A2 (pt) composição farmacêutica
ECSP17043318A (es) Composición que contiene quitina y proteínas digeribles
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112018076283A2 (pt) métodos e composições para potencializar terapias de célula tronco
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
BR112015015864A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112016010875A8 (pt) Composição útil para a promoção da fertilidade feminina
BR112018072064B8 (pt) Uso de triglicerídeos de cadeia média para preparação de composições nutricionais para proteção cardíaca em animais de estimação
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas
BR112019011802A2 (pt) composições nutricionais contendo butirato e/ou lactoferrina e usos das mesmas
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/202 (2006.01)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]